Becton Dickinson and (BDX) Upgraded at Citigroup

Becton Dickinson and (NYSE:BDX) was upgraded by equities researchers at Citigroup from a “sell” rating to a “neutral” rating in a report released on Friday, January 5th, Marketbeat.com reports.

Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research note on Tuesday, October 31st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 price target on shares of Becton Dickinson and in a research note on Tuesday, September 12th. Wells Fargo & Co initiated coverage on shares of Becton Dickinson and in a research note on Friday, September 22nd. They issued an “outperform” rating and a $225.00 price objective for the company. Evercore ISI initiated coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price objective for the company. Finally, Argus boosted their price objective on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $230.20.

Becton Dickinson and (BDX) traded up $1.89 on Friday, reaching $227.71. The company had a trading volume of 1,870,458 shares, compared to its average volume of 1,265,714. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. The stock has a market capitalization of $60,161.90, a price-to-earnings ratio of 48.97, a P/E/G ratio of 1.76 and a beta of 1.07. Becton Dickinson and has a 12 month low of $169.19 and a 12 month high of $229.68.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.12 earnings per share. analysts predict that Becton Dickinson and will post 10.66 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. KCS Wealth Advisory acquired a new position in Becton Dickinson and during the fourth quarter valued at $357,000. Nisa Investment Advisors LLC raised its position in shares of Becton Dickinson and by 21.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 107,472 shares of the medical instruments supplier’s stock worth $23,004,000 after acquiring an additional 18,638 shares during the period. Waverton Investment Management Ltd raised its position in shares of Becton Dickinson and by 9.0% in the fourth quarter. Waverton Investment Management Ltd now owns 432,388 shares of the medical instruments supplier’s stock worth $92,557,000 after acquiring an additional 35,776 shares during the period. Neville Rodie & Shaw Inc. acquired a new position in shares of Becton Dickinson and in the fourth quarter worth about $318,000. Finally, Atlantic Trust Group LLC raised its position in shares of Becton Dickinson and by 597.3% in the third quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock worth $88,381,000 after acquiring an additional 386,349 shares during the period. Institutional investors own 75.53% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/becton-dickinson-and-bdx-upgraded-to-neutral-by-citigroup.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply